Learn About Transthyretin Amyloid Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cleveland Clinic Main Campus
Mazen Hanna is a Cardiologist in Cleveland, Ohio. Dr. Hanna has been practicing medicine for over 33 years and is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Primary Amyloidosis, Heart Transplant, and Tenotomy.
Boston Medical Center Outpatient Pharmacy
Frederick Ruberg is a Cardiologist in Boston, Massachusetts. Dr. Ruberg is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Cardiac Ablation.
Brigham And Women's Hospital
Rodney Falk is a Cardiologist in Boston,, Massachusetts. Dr. Falk is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloidosis, Heart Transplant, and Cardiac Ablation.
Summary: Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid ...
Summary: The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with levels of circulating transthyretin amyloid aggregates (TAAs, a surrogate for amyloid disease activity) measured serially over time in patients with transthyretin cardiac amyloidosis (ATTR-CA). To accomplish this objective, the hypothesis that ...